New Anticoagulant Drugs For Treatment of Venous Thromboembolism and Stroke Prevention in Atrial Fibrillation

  • Tripodi A
  • Palareti G
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Venous thromboembolism (including deep vein thrombosis and pulmonary embolism) and atrial fibrillation are common conditions in Western countries. The mainstay of treatment and prevention for these diseases is fast-acting anticoagulant drugs such as heparins and vitamin K antagonists. The use of these drugs is, however, complex and demanding for both patients and physicians. Recently, new antithrombotic drugs which act directly by inhibiting activated coagulation factors such as factor X or thrombin have been developed and investigated in phase III clinical trials. The aim of this article is to review: (i) the need to develop new drugs; (ii) their efficacy/safety as demonstrated in clinical trials; (iii) the need for laboratory monitoring; and (iv) the direction towards the use of these new drugs in the real-life clinical situation.
© 2012 The Association for the Publication of the Journal of Internal Medicine

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • Armando Tripodi

  • Gualtiero Palareti

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free